Biogen Inc. Files 8-K: Other Events & Exhibits
Ticker: BIIB · Form: 8-K · Filed: May 12, 2025 · CIK: 875045
| Field | Detail |
|---|---|
| Company | Biogen Inc. (BIIB) |
| Form Type | 8-K |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulatory-filing
Related Tickers: BIIB
TL;DR
Biogen filed an 8-K on May 6th, check for updates.
AI Summary
Biogen Inc. filed an 8-K on May 12, 2025, reporting an event that occurred on May 6, 2025. The filing pertains to 'Other Events' and includes 'Financial Statements and Exhibits'. Specific details regarding the nature of the event or any financial figures were not provided in the excerpt.
Why It Matters
This filing indicates a material event or update from Biogen Inc. that requires disclosure to investors and the public.
Risk Assessment
Risk Level: low — The filing is a standard disclosure form without immediate negative or positive financial implications presented in the excerpt.
Key Players & Entities
- BIOGEN INC. (company) — Registrant
- May 6, 2025 (date) — Earliest event reported
- May 12, 2025 (date) — Date of report
- 225 Binney Street, Cambridge, Massachusetts 02142 (address) — Principal executive offices
FAQ
What specific event is reported under 'Other Events'?
The provided excerpt does not specify the nature of the 'Other Events' reported by Biogen Inc.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 6, 2025.
What is Biogen Inc.'s principal executive office address?
Biogen Inc.'s principal executive offices are located at 225 Binney Street, Cambridge, Massachusetts 02142.
What is the filing date of this 8-K report?
This 8-K report was filed on May 12, 2025.
What is Biogen Inc.'s standard industrial classification?
Biogen Inc.'s standard industrial classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 12, 2025 regarding BIOGEN INC. (BIIB).